The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
The platform, which its developers said is well suited to point-of-care testing, uses fluorescent polymers to distinguish between samples from cases and controls.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.
The initiative includes academic and private sector partners and aims to train new researchers in the early diagnosis of brain cancer.
A simple stool-based immunochemical test has shown promise during early trials in accurately ruling out the need for unnecessary colonoscopies.